Physician profile
John F Quertermus
NPI 1225015209
$482.09
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120.53 | 2019 | |
| Shionogi INC | $68.83 | 2019 | |
| Janssen Biotech, INC. | $59.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.42 | 2019 | |
| Ucb, INC. | $53.27 | 2019 | |
| Intercept Pharmaceuticals, INC. | $46.59 | 2019 | |
| Merck Sharp & Dohme LLC | $45.80 | 2019 | |
| Daiichi Sankyo INC. | $19.42 | 2019 | |
| Braintree Laboratories, INC. | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Quertermus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.